Brief: Acadia Pharmaceuticals Q3 EPS USD 0.2 Vs. IBES Estimate USD 0.14
06/11/2024 21:05
Nov 06 (Reuters) - Acadia Pharmaceuticals Q3 operating expenses USD 218.757 million. * Q3 net income USD 32.765 million vs. IBES estimate USD 24.5 million * Q3 pretax profit USD 38.806 million vs. IBES estimate USD 27 million * Q3 product sales USD 250.401 million vs. IBES estimate USD 248.8 million
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry